Category: failure to disclose COI

Amid lawsuits, toxicology journal corrects four asbestos papers for failure to cite author links to Georgia-Pacific

The journal Inhalation Toxicology has issued a fascinating correction notice covering four articles on various aspects of asbestos exposure by a group of researchers who failed to note their connection to Georgia-Pacific, the industrial giant that became caught up in a deluge of costly lawsuits over the carcinogenic chemical during the 1980s.

As the notice indicates, the ties weren’t mere tangents, but rather involved obvious — and obviously conflicting — relationships: Continue reading Amid lawsuits, toxicology journal corrects four asbestos papers for failure to cite author links to Georgia-Pacific

Coming clean: A major figure in cardiology publishes a lengthy conflict of interest correction in JAMA

Authors’ financial disclosures can be a thorny issue for scientific journals.  There’s often confusion over just what should be listed as a conflict of interest, and when relationships are revealed after papers are published, lack of disclosure sometimes leads to corrections.

For example, the Journal of Cell Science recently published this: Continue reading Coming clean: A major figure in cardiology publishes a lengthy conflict of interest correction in JAMA

Elsevier ob-gyn journal retracted paper after legal threat

When we broke the story last week about a juicy retraction notice in the American Journal of Obstetrics & Gynecology (AJOG) — known by its readers as “the Gray Journal” — we wrote that there was more to it than we suspected. That’s an understatement.

As we reported, the AJOG retracted an article that it had published earlier this year because 1) the author, Laurence Cole, had failed to disclose a potential financial conflict of interest with a pregnancy test maker named Church & Dwight; and 2) the article lacked a “credible scientific reason given for conducting the study,” along with other flaws detailed in the notice. (As we wrote the other day, we wonder why those issues did not arise during the initial review of the manuscript — but more on that shortly.)

We’ve since learned that the journal’s move came after it received a sharply worded letter from a high-powered San Francisco lawyer demanding immediate retraction of the article on the grounds that it represented a “substantial” threat to the financial health of his client. That client? A maker of home pregnancy tests who is now in the process of suing the very firm that provided Cole with research funding he failed to disclose.

First, here’s what Cole,  the hormone expert at the University of New Mexico whose paper the journal retracted, said about why he didn’t disclose that funding: Continue reading Elsevier ob-gyn journal retracted paper after legal threat

Ob-gyn journal pulls pregnancy test paper for undeclared conflict of interest, other problems

The American Journal of Obstetrics and Gynecology (AJOG) as a remarkable retraction notice in its November issue — the likes of which we haven’t seen before.

A little background: Earlier this year, Laurence Cole, an academic obstetrics specialist at the University of New Mexico in Albuquerque, published a paper in the AJOG looking at the wide variability in the hormone human chorionic gonadotropin, or hCG, during pregnancy (we’d link to the article, but the journal has pulled it, so here’s the abstract on Medline).

Cole runs — or did run until recently, more on that in a moment — the USA hCG Reference Service at the university, which purports to be the only lab in the world that can measure all forms of hCG. He has published extensively in this area of research, with at least 125 papers to his name on the subject, according to a Medline search. One of his websites puts the figure at 246.

So Cole was definitely a known quantity to the journal editors when he submitted his manuscript and when it was published online in February of this year. That’ll be more important in a bit. But first, the retraction notice: Continue reading Ob-gyn journal pulls pregnancy test paper for undeclared conflict of interest, other problems

Anil Potti failed to disclose corporate ties in yet-to-be-retracted JAMA papers

Anil Potti, the former cancer researcher whose work has become the subject of intense scrutiny that has already led to the retraction of five papers, didn’t tell the Journal of the American Medical Association (JAMA) about two very relevant corporate relationships he had when he published papers there, Retraction Watch has learned.

JAMA has published two papers by Potti and colleagues: 2008’s “Gene Expression Signatures, Clinicopathological Features, and Individualized Therapy in Breast Cancer,” and 2010’s “Age- and Sex-Specific Genomic Profiles in Non-Small Cell Lung Cancer.”

The Cancer Letter, which has been way out front in the Potti case, first reported Potti’s relationships with Eli Lilly and CancerGuide Diagnostics (formerly Oncogenomics, Inc.). As The Chronicle, Duke’s student newspaper, reported last September, the two companies cut their ties with Potti in July 2010 after allegations of misconduct and lying about a Rhodes Scholarship came to light.

But that was after the two papers were published, and Potti had relationships with both since 2006. As The Chronicle notes, he was a director at CancerGuide Diagnostics (formerly Oncogenomics, Inc.), and Continue reading Anil Potti failed to disclose corporate ties in yet-to-be-retracted JAMA papers